Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3502  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  » Next article
  » Previous article 
  » Table of Contents
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (149 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
   Abstract
   Introduction
   Materials and Me...
   Results
   Discussion
   Acknowledgements
   References
   Article Tables

 Article Access Statistics
    Viewed4839    
    Printed120    
    Emailed5    
    PDF Downloaded219    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 


 
ORIGINAL ARTICLE
Year : 2006  |  Volume : 54  |  Issue : 2  |  Page : 186-189

Comparison of valporic acid efficacy in familial versus sporadic cases of juvenile myoclonic epilepsy


Department of Neurology, Sina Hospital, Iranian Center for Neurological Research, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Sahraian Mohammad Ali
Department of Neurology Sina Hospital, Imam Khomeini Street, Hassan Abad Square, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 16804266

Rights and PermissionsRights and Permissions

  Abstract 

Background: Juvenile myoclonic epilepsy is a heterogeneous syndrome, both in genetic and clinical aspects. Aims: This study was conducted to compare the efficacy of valproic acid in familial versus sporadic cases of this syndrome. Settings and Design: Seventy patients with JME were identified; 24 patients (34.3%) had positive history of JME in their first degree relatives (group I) and 46 patients (65.7%) were sporadic (group II). Materials and Methods: Valproic acid was started for the patients with upward titration. The cases were followed for one year after final titration of the drug with regular blood monitoring. Patients, who had no myoclonic, absence and grand mal seizures within one year, were considered excellent responders. Statistical Analysis: We used Student T-test and Fisher's exact test for quantitative and qualitative variables respectively. Logistic Regression test was used to evaluate the predictive factors for final treatment outcomes. Results: Mean dosage of valproic acid was 800 mg/d in both groups (13 mg/kg and 12.4 mg/kg respectively). Mean therapeutic levels of the drug in group I and II were 74 µg/ml and 78.4 µg/ml respectively. Excellent responders' rate was 66.7% in group I and 76.1% in group II. History of absences and older age at the onset of grand mal seizures decreased excellent responders' rate in both groups. Conclusions: Considering response to valproic acid, there is no significant difference in familial versus sporadic cases of JME, whereas history of absences and older age at the onset of grandmal seizures, decrease the probability of being excellent responders in this syndrome.


Keywords: Juvenile myoclonic epilepsy, valproate, epilepsy treatment


How to cite this article:
Motamedi M, Mohammad Ali S, Rahmat M. Comparison of valporic acid efficacy in familial versus sporadic cases of juvenile myoclonic epilepsy. Neurol India 2006;54:186-9

How to cite this URL:
Motamedi M, Mohammad Ali S, Rahmat M. Comparison of valporic acid efficacy in familial versus sporadic cases of juvenile myoclonic epilepsy. Neurol India [serial online] 2006 [cited 2019 Sep 17];54:186-9. Available from: http://www.neurologyindia.com/text.asp?2006/54/2/186/25974



  Introduction Top


Juvenile myoclonic epilepsy (JME) is a common form of idiopathic generalized epilepsies, having an overall prevalence of 4-10%.[1],[2]

It is the most common form of idiopathic generalized epilepsies, especially in women. Isolated myoclonic jerks of arms, shortly after awakening are characteristic. Generalized tonic - clonic seizures often occur and one third of cases also have absences. Seizure occurrence is more likely with sleep deprivation, fatigue and alcohol withdrawal.[3]

Onset is usually in adolescence but seizures may begin or be diagnosed after the age of twenty.[4],[5]

A family history of epilepsy is common and there is evidence for linkage of the disease to chromosomes 6p and 15q.[6],[7]

The EEG background is typically normal and the characteristic interictal EEG findings are generalized 4-6 Hz polyspike and slow wave complexes, however, many patients have 3-4 Hz spike and slow wave complexes. More than half of patients may show normalization of EEG after drug therapy.[1]

Valporic acid is currently the drug of choice and is reported to control the seizures in 80% of patients.[8] Previous studies showed that those with all three seizure types are more likely to be poor responders[9],[10] and as JME is both genetically and clinically heterogeneous,[3] we conducted this study to see if there is any difference between familial and sporadic cases in response to valproic acid.


  Materials and Methods Top


Seventy patients (48 F, 22M) with JME were studied. Study protocol (after getting approval from university ethics committee) was sent to our colleagues in general neurology clinics of the hospital and subjects with impression of JME were referred to epilepsy clinic. Cases were included according to the following criteria:

1. History of myoclonic jerks with history of generalized tonic-clonic seizures or absence at times.

2. Age at the onset between 8-25 years old.

3. At least one EEG with fast spike - slow waves or poly spike - slow wave complexes and normal background.

Patients with mental retardation, history of sever head injury, pregnancy during the study and structural brain lesions, revealed by MRI, were excluded. Informed consents were obtained from the cases before inclusion.

Demographic data, family history of seizures, details about myoclonic jerks, generalized tonic- clonic seizures, absences, valproate associated adverse effects, any discontinuation and reasons, number of seizures at base line, during titration and after stable valproate dose, results of MRI and EEG were all registered. The patients who had family history of JME in their first degree relatives were considered familial (group I) and sporadic cases defined as those who had no history of seizure in their families (group II). Sodium Valproate (Tablet 200 mg) 400-600 mg/day started in these patients, upward titration was performed over a six weeks period until the patients were seizure free, intolerable side effects occurred, or a maximum dose of 60mg/kg was reached and they were included in the study groups after eight weeks of treatment.

During drug escalation the patients were visited every 2-4 weeks and blood monitoring (CBC-LFT) was conducted. All the patients were followed for one year based on frequency of different types of seizures. Within one year following final titration of the drug, the patients were divided into two groups. Patients who had no myoclonic, absence and grandmal seizures were considered as excellent responders and the remaining patients were identified as non excellent responders.

We used student T-test for comparison of quantitative variables and Chi-square or Fisher's exact test for qualitative ones. Variables that could be related to excellent response were subjected to analysis with a logistic regression procedure and forward stepwise selection. Dependent variables coded as zero for excellent response and one for other results. Odds ratio with 95% confidence interval assessed for one. Variables like age, sex, family history in the first degree relatives, history of absences, age at the onset of generalized tonic- clonic seizures, daily dose of valproic acid and its serum level (total of 7 variables) were included in the model as predictive factors. The maximum likelihood approach was used to estimate weights of the logistic parameters. Statistical analysis was performed using SPSS software (SPSS Inc, Chicago, IL).


  Results Top


Seventy patients met selection criteria. 24 patients (34.3%) had history of JME in their first degree relatives (group I) and 46 patients (65.7%) were without positive family history (group II). The patients in group I (18women, 6 men) ranged from 16 to 36 years, the group II (30 women, 16 men) ranged from 13 to 50 years. Both groups were comparable in age (mean 23.9 vs. 23.8), sex and age at the onset of myoclonic seizures (mean 14.8 vs. 14.5 years) age at the onset of absence seizures and also with respect to the frequency of their myoclonic, absence and grandmal seizures. We could not find any significant differences between age at the onset, type of seizures, response to treatment, serum valproate level and side effects of treatment in two groups [Table - 1][Table - 2]. Mean dosage of valproic acid was 800 mg/day (Range 400-1500) in both groups (13 mg/kg and 12.4 mg/kg respectively).

Mean therapeutic serum levels of the drug were 74 mg/ml (Range 50-99 mg/ml) in familial and 78.4 mg/ml (Range 54-131 mg/ml) in sporadic cases. During the study all the patients had more than 50% reduction in their seizures and excellent responders (seizure free) were 66.7% in group I and 76.1% in group II.

Sleep deprivation was the most common precipitating factor for seizures (72.9%) and the others, in order of decreasing frequencies, were stress, fatigue, drug withdrawal, hunger and alcohol [Table - 3]. The mean daily dosage of valproic acid was 12.35 mg/kg (Range 7-25) in excellent responders and it was 13.1 mg/kg (Range 6-31) in non excellent responders.

Statistical analysis with logistic regression showed that history of absence seizures and age at the onset of generalized tonic - clonic seizures were predictive for non- excellent response to treatment ( P =.01).

The odds ratio for absence seizures was 5.72 and for age at the onset of GTCS was 1.21


  Discussion Top


Juvenile myoclonic epilepsy has been one of the most extensively studied epilepsy at the molecular levels as this syndrome has the advantage of being a common familial epilepsy with well defined clinical and EEG features. Despite being a familial disorder, significant number of cases (about one- half to one third) is sporadic. It is possible that the sporadic cases could be genotypically different or similar as compared with the familial ones.[11]

This study conducted to compare efficacy of valproic acid in familial versus sporadic cases. In our study 34.3% of the patients had family history of JME and 28% had a prior history of absence seizures. They were almost the same comparing to the other reports.[12],[13]

Sporadic and familial cases of some neurological conditions may have differences in clinical manifestations and course. In Parkinson's disease family history is accompanied by earlier age at the onset of disease and also slower motor and mental decline.[14]

Torelli et al showed that age at the onset, is significantly lower in women with familial cluster headache comparing to sporadic cases[15] and familial Alzheimer disease has some special clinical and pathological characteristics.[16] On the other hand, in some diseases like migraine and multiple sclerosis the authors could not find any significant difference between familial and sporadic cases.[17],[18]

As mentioned earlier, the over all clinical characteristics of familial and sporadic cases were similar. We could not find any significant difference between these two groups in response to valproic acid therapy, serum levels and side effects of the drug. This shows that valproate is equally effective in both groups and positive family history does not affect the prognosis.

Alcohol is considered as a common precipitating factor in other studies but it was one of the unusual precipitants in our cases. This may be explained by cultural differences, low prevalence of alcohol consumption and lack of reporting.

An interesting point was that the mean daily dose of valproate in excellent responders was 12.35 mg/kg (Rang 7-25), which is less than the standard recommended dose of 20-40 mg/kg.This may be due to differences in drug metabolism or protein binding. Controlling seizures with lower dosage has also been described in some other studies which help in reducing the toxic effects and increasing compliance of patients.[13]

It should be mentioned that history of absences and age at the onset of GTCS independently affect response to valproic acid. For history of absence seizures the odds ratio was 5.72 (1.51-21.69 CI= 95% P = 0.01).This means that a patient with history of absence seizures has approximately 5.7 times more chance to be in non excellent responders. For the age at the onset of GTCS the odds ratio was 1.21 (1.07-1.37 CI= 95% P = 0.02).This also shows that one year increase in age at the onset of GTCS increases this probability by 1.7 times. Other studies also reported that history of absences, or suffering from three seizure types in JME, increase probability to be a non responder to valproate therapy.[9],[10]

Lack of genetic study and information about protein binding or drug metabolism in excellent and non excellent responders are our main limitations in this study.

Recognition of clinical subtypes among JME patients (especially excellent responders) could have therapeutic implications and help to improve the characterization of JME phenotypes. Conducting molecular studies in these subgroups may yield valuable information and we suggest more evaluations regarding genetic analysis and response to treatment in this syndrome.


  Acknowledgements Top


We would like to acknowledge Dr. P. Tajic for her valuable assistance in statistical analysis and Mr. Hejrani for secretarial helps.

 
  References Top

1.Wheless JW, Kim HL. Adolescent seizures and epilepsy syndromes. Epilepsia 2002;43:33-52.   Back to cited text no. 1    
2.Trescher WH, Lesser RP. The epilepsies. In : Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in clinical practice. 4th ed. Butterworth - Heinemann: Philadelphia; 2004. p. 1963 - 5.   Back to cited text no. 2    
3.Zifkin B, Andermann E, Andermann F. Mechanisms, genetics and pathogenesis of juvenile myoclonic epilepsy.Curr Opin Neurol 2005;18:147-53.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Jha S, Mathur VN, Mishra VN. Pitfalls in Diagnosis of Epilepsy of Janz and its Implications. Neurol India 2002;50:467-9.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Murthy JM. Factors of error involved in the diagnosis of juvenile myoclonic epilepsy: A study from South India. Neurol India 1999;47:210-3.  Back to cited text no. 5    
6.Suzuki T, Delgado-Escueta AV, Aguan K, Alonso ME, Shi J, Hara Y, et al . Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 2004;36:842-9.   Back to cited text no. 6    
7.Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, Pang KA, et al . Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Genet 1997;6:1329-34.  Back to cited text no. 7    
8.Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, et al . Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60:1100-5.   Back to cited text no. 8    
9.Jain S, Tripathi M, Srivastava AK, Narula A. Phenotypic analysis of Juvenile myoclonic epilepsy in Indian families. Acta Neurol Scand 2003;107:356-62.  Back to cited text no. 9    
10.Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drug resistance in juenile myoclonic epilepsy. J Neurol Neurosurg Psychiatr 2001;70:240-3.   Back to cited text no. 10  [PUBMED]  [FULLTEXT]
11.Briellmann RS, Torn-Broers Y, Berkovic SF. Idiopathic Generalized Epilepsies: Do Sporadic and Familial Cases Differ? Epilepsia 2001;42:1399-402.  Back to cited text no. 11  [PUBMED]  [FULLTEXT]
12.Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of janz. Neurology 1984;34:285-94.  Back to cited text no. 12  [PUBMED]  
13.Panagariya A, Sureka RK, Sardana V. Juvenile Myoclonic Epilepsy: an experience from north western India. Acta Neurol Scand 2001;104:12-6.  Back to cited text no. 13  [PUBMED]  [FULLTEXT]
14.Inzelberg R, Schecthman E, Paleacu D, Zach L, Bonwitt R, Carasso RL, et al . Onset and progression of disease in familial and sporadic Parkinson's disease. Am J Med Genet A 2004;124:255-8.  Back to cited text no. 14    
15.Torelli P, Manzoni GC. Clinical observations on familial cluster headache. Neurol Sci 2003;24:61-4.  Back to cited text no. 15  [PUBMED]  [FULLTEXT]
16.Marcon G, Giaccone G, Cupidi C, Balestrieri M, Beltrami CA, Finato N, et al . Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 2004;63:199-209.  Back to cited text no. 16    
17.Weinshenker BG, Bulman D, Carriere W, Baskerville J, Ebers GC. A comparison of sporadic and familial multiple sclerosis. Neurology 1990;40:1354-8.  Back to cited text no. 17  [PUBMED]  
18.Rainero I, Valfre W, Gentile S, Lo Giudice R, Ferrero M, Savi L, et al . A comparison of familial and sporadic migraine in a headache clinic population. Funct Neurol 2002;17:193-7.  Back to cited text no. 18    


    Tables

[Table - 1], [Table - 2], [Table - 3]

This article has been cited by
1 Juvenile myoclonic epilepsy
Alfradique, I., Vasconcelos, M.M.
Arquivos de Neuro-Psiquiatria. 2007; 65(4 B): 1266-1271
[Pubmed]
2 Comparison of valporic acid efficacy in familial versus sporadic cases of juvenile myoclonic epilepsy: Invited comments
Kothare, S.
Neurology India. 2006; 54(2): 189
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow